Biogen Idec
NASDAQ:BIIB
$119.70
-$0.30
(-0.25%)
Quote as of 4:00 PM EST on 02/14/12
|
$119.70
-$0.30
(-0.25%)
|
|
| Today's Open | $118.61 |
|---|---|
| Previous Close | $120.00 |
| Daily Range | $118.12 - $120.08 |
| 52-Week Range | $65.66 - $123.23 |
| Market Cap | $28.58B |
| P/E Ratio | 23.81 |
| Dividend (Yield) | $0.00 (0.0%) |
| Volume | 1,029,399 |
| Average Daily Volume | 1,806,659 |
| Current FY EPS | $6.12 |
BIIB Information
| Description |
|---|
| The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies. |
| Sector |
| Healthcare |
| Industry |
| Biotechnology |
News & Commentary
Biogen To Pay Up To $562.5 Million To Acquire Private Biotech Stromedix
Elan's 4Q Loss Wider Than Expected - Analyst Blog
UPDATE: Biogen To Pay Up To $562.5 Million for Private Stromedix
Top Analyst Upgrades & Downgrades (ALTR, AMSC, BIIB, CELG, COH, CSTR, COP, FSLR, GILD, HAIN, MA, RF,
Forget Big Pharma, It Is Time For A Biotech ETF - ETF News And Commentary
3 Biotechnology Stocks for Short-Term Traders
How Many Stocks Should You Own? - Investment Ideas
Has Elan Become the Perfect Stock?
Biogen: Government Investigating Company's Promotional Practices
The Disadvantage of a Successful Pipeline
